• 1
    Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals Part 1: blood pressure measurement in humans a statement for professionals from the subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142161.
  • 2
    Myers MG, Oh PI, Reeves RA, et al. Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens. 1995;8:591597.
  • 3
    Owens P, Atkins N, O’Brien E. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. Hypertension. 1999;34:267272.
  • 4
    Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14:12631269.
  • 5
    Gustavsen PH, Hoegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J Hum Hypertens. 2003;17:811817.
  • 6
    Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens. 2009;27:280286.
  • 7
    Mancia G, DeBacker G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 8
    Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Staessen JA, on behalf of the International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007;115:214552.
  • 9
    Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office – recognizing the problem and proposing the solution. Hypertension. 2010;55:195200.
  • 10
    O’Brien E. Ambulatory blood pressure measurement: the case for implementation in primary care. Hypertension. 2008;51:14351441.
  • 11
    Hansson L, Zansson L, Zanchetti A, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:17551762.
  • 12
    Mancia G, Omboni S, Parati G, et al. Twenty-four hour ambulatory blood pressure in the hypertension optimal treatment (HOT) study. J Hypertens. 2001;19:17551763.
  • 13
    Staessen JA, Fagard R, Thijs L, et al. Ramdomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757764.
  • 14
    Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539546.
  • 15
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):18871898.
  • 16
    Pinto E, Bulpitt C, Beckett N, et al. Rationale and methodology of monitoring ambulatory blood pressure and arterial compliance in the hypertension in the very elderly trial. Blood Press Monit. 2006;11:38.
  • 17
    Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA. 1988;259:225228.
  • 18
    Myers MG, Reeves RA. White coat effect in treated hypertensive patients: sex differences. J Hum Hypertens. 1995;9:729733.